Merck Sharp + Dohme Corp.

Msd R&d (china) Co., Ltd.

Msd R&d Co., Ltd.

Jonathan E Wilson

Dong-Ming Shen

Deping Wang

Petr Vachal

Christopher Joseph Sinz

Shimin Xu

Meng Yang

Troy McCracken

Zack Zhiqiang Guo

Andrew William Stamford

Jared N Cumming

Yimin Qian

Michael P Dwyer

Melissa S Egbertson

Jack D Scott

Shawn J Stachel

Daniel Vincent Paone

Ulrich Iserloh

XiaoXia Qian

Santhosh Francis Neelamkavil

Rajan Anand

Richard Berger

Fengqi Zhang

Pengcheng Patrick Shao

Vincent Colandrea

Bart Harper

Alejandro Crespo

Kake Zhao

Vanessa L Rada

Yili Chen

Dann Parker

Ming Wang

Ravi Kurukulasuriya

Timothy A Cernak

Haitang Li

Aaron Zwicker

Maud Reiter

Dong Ming Shen

Troy Mccracken

Vincent J Colandrea

Zack Zhi Qiang Guo

The present invention is directed to dihydropyrazolopyrimidinone compounds of formulas (I) and (II) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. 

Bicyclic heterocyclic compounds as PDE2 inhibitors

The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. 

Pyrazolyl pyrimidinone compounds as PDE2 inhibitors

The present invention is directed to substituted pyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. 

Heteroaryl-pyrimidinone compounds as PDE2 inhibitors

Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof. 

Pyrimidone carboxamide compounds as PDE2 inhibitors

3,3'-Disubstituted indoline compounds, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.

3,3'-disubstituted indolines as inhibitors of cholesterol ester transfer protein

In its many embodiments, the present invention provides certain C5-spiro iminothiadiazine dioxide compounds, including compounds Formula (I): (structurally represented) or tautomers thereof, and pharmaceutically acceptable salts of said compounds, wherein R1, R2, R3, X, Y, s, ring A, RA, m, -L1-, and RL are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed. 

C6-spiro iminothiadiazine dioxides as BACE inhibitors, compositions, and their use

Compounds having the structure of Formula Ia, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. 

Substituted benzopiperazines as CETP inhibitors

Growing community of inventors

South Orange, NJ, United States of America

Jonathan E Wilson